title: Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
abstract: Early relapse is common in patients with mantle cell lymphoma (MCL) highlighting the unmet need for further improvement of therapeutic options for these patients. CD20 inhibition combined with induction chemotherapy as well as consolidation with high-dose chemotherapy (HDCT) is increasingly considered cornerstones within current therapy algorithms of MCL whereas the role of radioimmunotherapy is unclear. This retrospective single center study compared 46 consecutive MCL patients receiving HDCT in first or second remission. Thirty-five patients had rituximab and BEAM (R-BEAM), and 11 patients received ibritumomab tiuxetan (Zevalin®), an Yttrium-90 labeled CD20 targeting antibody, prior to BEAM (Z-BEAM) followed by autologous stem cell transplantation (ASCT). We observed that the 5-year overall survival (OS) in the R-BEAM and Z-BEAM groups was 55% and 71% (p = 0.288), and the 4-year progression free survival (PFS) was 32% and 41%, respectively (p = 0.300). There were no treatment related deaths in both groups, and we observed no differences in toxicities, infection rates or engraftment. Our data suggest that the Z-BEAM conditioning regimen followed by ASCT is well tolerated, but was not associated with significantly improved survival compared to R-BEAM. Copyright © 2015 John Wiley & Sons, Ltd.
authors.affiliation: Department of Medical Oncology, University Hospital, Berne, Switzerland.
authors.forename: Martin D
authors.initials: MD
authors.lastname: Berger
authors.affiliation: Department of Medical Oncology, University Hospital, Berne, Switzerland.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Branger
authors.affiliation: Department of Nuclear Medicine, University Hospital, Berne, Switzerland.
authors.forename: Bernd
authors.initials: B
authors.lastname: Klaeser
authors.affiliation: Department of Hematology, University Hospital, Berne, Switzerland.
authors.forename: Behrouz Mansouri
authors.initials: BM
authors.lastname: Taleghani
authors.affiliation: Department of Medical Oncology, University Hospital, Berne, Switzerland.
authors.forename: Urban
authors.initials: U
authors.lastname: Novak
authors.affiliation: Institute of Pathology, University of Berne, Berne, Switzerland.
authors.forename: Yara
authors.initials: Y
authors.lastname: Banz
authors.affiliation: Department of Clinical Research, University of Berne, Berne, Switzerland.
authors.forename: Beatrice U
authors.initials: BU
authors.lastname: Mueller
authors.affiliation: Department of Medical Oncology, University Hospital, Berne, Switzerland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Pabst
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D064592:Autografts; D002330:Carmustine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000401:mortality / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage; D000069283:Rituximab / Q000008:administration & dosage*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D019172:Transplantation Conditioning
chemical_list: D000911:Antibodies, Monoclonal; D003561:Cytarabine; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine
keywords: BEAM; Yttrium-90 ibritumomab tiuxetan; autologous transplantation; mantle cell lymphoma; radioimmunotherapy; rituximab; zevalin